Since immune responses to vaccines can differ around the world, these findings are encouraging for the development of an effective Ebola vaccine for Africa,» said Merlin Robb, M.D., Director for Clinical Research at the US Military HIV Research Program (MHRP), whose site in Uganda, Makerere University Walter Reed Project (MUWRP), conducted the study.
This premature enthusiasm has more recently given way
to caution as the technology has gradually been transferred
to humans, with only limited short - term success.3 Finally,
since HIV usually enters the body through mucosal surfaces — the vagina and rectum — augmenting an
immune response at these portals of entry by using what scientists call mucosal AIDS
vaccines might be an additional way
to improve protection against infection.